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Ethical review by expert committee continues to be the ﬁrst line of defence when it comes to protecting
human subjects recruited into clinical trials. Drawing on a large scale study of biomedical experimen-
tation across South Asia, and speciﬁcally on interviews with 24 ethical review committee [ERC] members
across India, Sri Lanka and Nepal, this article identiﬁes some of the tensions that emerge for ERC
members as the capacity to conduct credible ethical review of clinical trials is developed across the
region. The article draws attention to fundamental issues of scope and authority in the operation of
ethical review. On the one hand, ERC members experience a powerful pull towards harmonisation and a
strong alignment with international standards deemed necessary for the global pharmaceutical
assemblage to consolidate and extend. On the other hand, they must deal with what is in effect the
double jeopardy of ethical review in developing world contexts. ERC members must undertake review
but are frequently made aware of their responsibility to protect interests that go beyond the ‘human
subject’ and into the realms of development and national interest [for example, in relation to literacy and
informed consent]. These dilemmas are indicative of broader questions about where ethical review sits in
institutional terms and how it might develop to best ensure improved human subject protection given
growth of industry-led research.
Crown Copyright  2014 Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).From time to time, terms appear in the social sciences which
help in capturing a biomedical zeitgeist. Notions such as ‘medical-
ization’ and ‘geneticisation’ (Lipmann, 1991; Hedgecoe, 1998; Have,
2001) have in the past provided a simple shorthand for the ways
that social, economic and technological changes begin to reshape
the landscape of health care and the experience of those that pass
through it. In similar fashion, pharmaceuticalisation has entered
social science discourse. Williams et al. (2011) provide a critical
evaluation of this concept and its utility in understanding the
pervasive impact of pharmaceuticals within medical systems,
economies and societies (also see (Abraham, 2011)). Consistent
with their intention to give greater speciﬁcity to the pharmaceu-
ticalisation thesis, we set out in this article to interrogate some of
the ‘upstream (macro) level processes’ (2011: 712) that comeSimpson).
evier Ltd. This is an open access awithin the ambit of pharmaceuticalisation. The arena we consider
is onewhich is increasingly important in understanding the growth
and development of pharmaceuticals in society but one that is
often lost in a bias towards Euro-American accounts of this process.
Here we bring together globalisation, governance and the ethical
review of clinical trials involving human subjects in the developing
world. The main sites we consider are research ethics committees
and the responses of their members to a growing number of pro-
tocols for industry-sponsored clinical trials. What we show through
this analysis is the way that the growing engagement with phar-
maceutical interests across South Asia produces signiﬁcant tensions
for ERC members. Beneath the documentary and procedural claims
to standardisedmeasurement, rules and disinterested evaluation in
ethical review, industry-sponsored clinical trials generate concerns
about scope, legitimacy and authority for those whose job it is to
undertake and develop credible ethical review (cf Timmermans and
Almeling, 2009; Timmermans and Epstein, 2010). Whilst such
tensions are likely to be evident in any context where researchrticle under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
Table 1
The BHESA interview data-set.
Category Nepal India Sri Lanka US, UK Total
PIs and Co-Is 10 31 11 3 55
Clinical research assistants 14 18 11 0 43
Other trial staff 24 22 39 0 85
Collaborators 0 3 1 1 5
Sponsors and CRO staff 0 35 1 13 49
Ethics committee members 6 14 6 0 26
Regulators 2 7 2 6 17
Other key informants 17 18 9 13 57
Total 73 148 80 36 337
1 The research was funded by the Economic and Social Research Council of the
United Kingdom in collaboration with the Department for International Develop-
ment [ESRC/DfID nbrRES-167-25-0503]. Ethical approval for the study was initially
given by the School of Social and Political Sciences Research Ethics Committee,
University of Edinburgh [13/10/2010]. Ethical clearance was then gained from local
ERCs for research to be carried out in India, Nepal and Sri Lanka.
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world settings there are other factors in play that give these
questions a particular urgency and complexity.
Our stepping off point in considering the relationship between
ethical review and clinical trials in South Asia is a question posed by
Rachel DouglaseJones in her doctoral thesis on capacity-building in
ethical review in Asia: ‘what are the problems to which the ethics
committee is a solution?’ [2013, p34]. The question is an important
one. Ethical review committees play a crucial role in the regulation
of experimentation involving human beings. In the most basic of
terms, the approval of a formally constituted body of experts should
ensure that research is beneﬁcial, scientiﬁcally valid, and, above all,
safe for those who participate. Yet, whereas in Europe and North
America ERCs may have reached a degree of institutional integra-
tion and stability, they are still very much in a state of development
in parts of the world that have only recently been drawn into the
rapidly growing demand for experimentation involving human
subjects. South Asia is a case in point. Capacity for ethical review is
rapidly developing across the region and ERCs currently follow a
broadly similar institutional and procedural format. Regional
capacity-building has developed in association with organisations
like the Forum for Ethical Review Committees in Asia and the
Western Paciﬁc (FERCAP), the Strategic Initiative for Developing
Capacity in Ethical Review (SIDCER) and the Global Forum on
Bioethics (GFB) all of whichwork to build capacity when it comes to
the review of projects locally. Afﬁliation to these organisations and
the establishment of local branches [for example, FERC e Sri Lanka
and FERC e India] is an important route to harmonisation and the
dissemination of good practice. Arguably however, the more
powerful source of standardisation for review of industry con-
ducted trials has been the ICH-GCP guidelines which aim to provide
‘a more economical use of human, animal and material resources,
and the elimination of unnecessary delay in the global develop-
ment and availability of new medicines whilst maintaining safe-
guards on quality, safety and efﬁcacy, and regulatory obligations to
protect public health’ (ICH, 2005). Drawing on a genealogy of crisis
reaching back to the Declaration of Helsinki, the ICH-GCP lays down
detailed benchmarks for the ethical and scientiﬁc conduct of trials.
Yet, linking the work of ERCs with a genealogy of universal human
rights in this way provides signiﬁcant cover for the extension of
commercial pharmaceutical research (Abraham, 2007; Abraham
and Reed, 2002). In this view, ERCs are the handmaiden rather
than the governor of trial activity with ethical review seen as
essentially procedural, bureaucratic and rule observing. Earlier
studies suggest that in countries that have embraced standard
guidelines and particularly the ICH-GCP guidelines, ERCs are apt to
operate in ways that appear to be more about legal defence of re-
searchers rather than actual protection of subjects (Bosk, 2007;
Kleinman, 1999; Stark, 2012). Our analysis conﬁrms these con-
cerns, and shows ethics committee members raising issues that are
not limited to human subject protection per se but drawing in a
range problems which afﬂict large numbers people in their society
[for example, poor access to resources, corruption, illiteracy,
inequality to name but a few]. These issues are articulated at a
variety of scales [the person, the hospital, the University, the
research community, the vulnerable, the nation state, the devel-
oping world and so forth]. Yet, the reality faced by many ERC
members is one of growing pressure to accomplish human subject
protection by narrowing the focus of ethical review such that it is
clearly in line with industry speciﬁed guidelines.
1. Methods
The data onwhich this paper is based are drawn from a study of
the growth of clinical trials and human experimentation in SouthAsia [India, Nepal and Sri Lanka].1 In this study we identiﬁed key
actors in the conduct, management and regulation of clinical trials
in a variety of settings (See Table 1).
In total we carried out 337 semi-structured interviews, the vast
majority of which were recorded, translated into English where
necessary, and transcribed. The resulting dataset was entered into
Atlas.ti for coding. The codes were generated by an iterative process
at aworkshop held inMumbai with all coders present; trial codings
were carried out and a selection of interviews was recoded to
ensure consistency.
Here we draw principally on extended interviews with a small
sub-set of Ethical Review Committee [ERC]members from India [14],
Sri Lanka [6] and Nepal [6]. In many respects, the sample is unrep-
resentative of the wider body of reviewers at work in each of these
countries as it was self-selecting and therefore tended to bemade up
of people who were knowledgeable, articulate and keen to express
their viewson the rights andwrongsof clinical trials, theworkofERCs
and their less responsible colleagues. They were also mostly from
Institutional [hospital] and University settings. Nonetheless, consid-
eration of their accounts of topics such as ethical review, operation
and composition of committees, capacity building, training for re-
viewers and approaches to informed consent provides a useful indi-
catorof themajor challenges facedbycommittedERCmembers in the
settings identiﬁed.We also draw to a lesser extent on interviewswith
regulators, policy-makers, academics and investigators involved in
developing ethical review infra-structure. Before considering these
responses in detail it is necessary to consider brieﬂy the three con-
texts in which our study took place.2. India
India has a well-established pharma industry dating back to the
1950s. The thrust of this industry has been the production of ge-
nerics for local markets. This infrastructure, combined with large
numbers of English speaking doctors and technicians, as well as
large populations of treatment naive people with a range of dis-
orders of interest in the west [e.g. cancers, cardio-vascular disease,
diabetes] has stimulated much interest in clinical trials. Trials are
outsourced by western pharmaceutical industries as well as con-
ducted by local companies keen to move into global markets for
their products. Acceleration in this sector of activity has over-
whelmed existing machinery for ethical review and monitoring
which previously catered mostly for locally conducted research.
Along with Ethical Guidelines for Biomedical research Involving
Human Subjects Indian Council of Medical Research (2000), the
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of ethical and scientiﬁc conduct of trials. In 2001, ICH-GCP India
were created (CDSCO, 2001), adapting the generic guidelines to ﬁt
local circumstances. In 2005, the ‘Schedule Y’ amendment of the
Drugs and Cosmetic Act provided further guidance on the consti-
tution and responsibilities of ethics committees. To date, ERCs have
largely operated within the institutions in which the trials have
taken place. The ICMR has launched various initiatives to encourage
the take up of standard operating procedures against a backdrop of
poor regulation and variable quality of the review process. The
Forum for Ethical Review Committees e India [FERCI] was estab-
lished under the auspices of FERCAP to improve quality and stan-
dards and held its ﬁrst conference in 2011. In 2007, the ICMR
established its own clinical trials registry.2 At the time of writing,
there over 650 ERCs registered via the Clinical Trials Registry of
India.3 The workload of ERCs is unevenly spread with a relatively
small number of ERCs dealing with the majority of trials and a
disproportionate number using independent ERCs.3. Sri Lanka
Sri Lanka has neither the population nor the pharmaceutical
industry that India has. Not surprisingly therefore, the develop-
ment of ERCs looks very different. All the major medical faculties
and teaching hospitals currently have their own institutional
ethical review committees, making for some 15 committees
(Dissanayake et al., 2006). The Sri Lanka Medical Association
(SLMA) formed its ethics committee in 1991 and began considering
research projects carried out by its members in 1999. In 2005, the
Forum for Ethical Review Committees in Sri Lanka [FERCSL] was
established along with Uniform Guidelines for ethical review
(Dissanayake et al., 2006). However, take-up of the guidelines ap-
pears patchy with considerable variation in standard operating
procedures in evidence. The increase in the number of ERCs and the
quality of their capacity to review projects was in part driven by an
increase in international collaborative research being conducted in
Sri Lanka as well as by the desire to create robust research gover-
nance of the kind needed to attract trials in the future. Sri Lanka has
also recently created its own clinical trials registry.4 As in India,
ERCs are a keymechanism in the regulation of trial activity but they
are also identiﬁed as having serious weaknesses that need to be
addressed if they are to be effective (Karunananyake, 2012).4. Nepal
Nepal is by far the smallest player in the emergence of human
experimental activity in Asia and consequently has a very recent
and modest history of ethical review. The central body regulating
research studies in Nepal is the apex Ethical Review Board (ERB) of
Nepal Health Research Council. The 20 Institutional Review Com-
mittees (IRCs) that operatemostly in themedical schools have been
approved by the national ERB. The IRCs came in existence because2 The Clinical Trials Registry India. http://www.who.int/ictrp/network/ctri/en/
index.html accessed 23rd July 2013 http://www.who.int/ictrp/network/ctri/en/
index.html accessed 23rd July 2013.
3 Details of registered ERCs can be found on the website of the Central Drugs
Standard Control Organisation: http://www.cdsco.nic.in/forms/Default.aspx
accessed 5th Feb 2014.
4 The Sri Lanka Clinical Trials Registry (SLCTR) is a Registry for clinical trials
involving human subjects, conducted in Sri Lanka or overseas. The SLCTR is a Pri-
mary Registry linked to the Registry Network of the International Clinical Trials
Registry Platform of the WHO (WHO-ICTRP). It is a not-for-proﬁt Registry, with free
and open access to researchers, clinicians, and the general public’. http://www.slctr.
lk/accessed 21st July 2013.of increasing volume of local research studies seeking approval
from ERB. IRCs are not currently authorised to review international
trials which must be reviewed at ERB level. National Ethical
Guidelines for Health Research in Nepal were published in 2001. A
National Guideline on Clinical Trials with the use of Pharmaceutical
Products was published in 2005. Phase I and Phase II trials are not
currently allowed and as a consequence Nepal has not been a target
for growth in these activities with the increase in research mostly
being carried out by international charities, NGOs and academic
bodies (Khatri et al., nd).5. The rise of human experimentation in Asia
The earlier attitude was that we should block it [clinical trials
development] because as I told you it was a nation of traders at that
time and now because our own people are innovating, we want the
innovation to be there, we want to be landscaped for the innova-
tion, so the trials are to be permitted but then at the same time the
ethical standards have moved up, benchmarks have increased,
every trial has to be put on the web and everything has to be on the
web, so it is an open system, so in that you don’t feel threatened;
not at all but the only thing, I feel heavy as a person. Senior
Government of India Ofﬁcial [022]
.[ the government].. want to promote clinical trials more as a
money making exercise than anything else I guess, because clinical
trials are big money, and we have a good receptive population here,
educated and also the free health care which means that people
need not bother about funding health care for the patients with side
effects or anything, that automatically falls on the state to fund all
that, so it’s a very practical place for clinical trials. Sri Lanka ERC
member [71]
Before 1990, there are people who brought medicines in bags and
distributed but after the formation of Nepal Health Research
Council in 1991, every health research in the country should take
ethical approval from them. I am dead against clinical trials. My
soul just doesn’t agree to it. There are vulnerable groups like poor
people, army, students, handicapped people who are being tested.
We should not encourage it [clinical trials].[]. Newer biological
products should not be tested in humans. There are also DDA
regulations to be cleared in Nepal. NepalERC member [03]
In the three quotations given above, something of the ambiva-
lence that those with responsibility for ethical review feel about
clinical trials sponsored by commercial trials organisations is
evident. On the face of it, the economics of experimentation are
undoubtedly attractive. Saving costs on drug development, opening
up new markets and even developing entirely new drugs using
local expertise has the potential to reconﬁgure the shape of the
pharmaceutical industry across the globe. In anticipation of such
developments, extravagant claims have been made for the contri-
bution that clinical trials will, in due course, make to economies in
the region and particularly in India. These claims have stimulated
the promotion of trials, training of personnel and capacity building
in the knowledge and expertise needed to conduct trials in accor-
dance with international standards. Much of this activity is inten-
ded to create a climate inwhich home-grown as well as outsourced
clinical trials will thrive; the promise is nothing short of a phar-
maceutical El Dorado.
On the way to this El Dorado, however, serious concerns have
been raised. Many of these concerns are by now familiar and well-
rehearsed; they draw attention to the potential for abuse and
exploitation of ‘human subjects’ in trials. This may range from the
inadequacy of informed consent procedures through to physical
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there may then be little or no compensation, giving rise to charges
that local populations are used as ‘guinea pigs’ with ‘double stan-
dards’ in operation (Macklin, 2004). There are concerns that groups
rendered vulnerable by their marginality, poverty and lack of lit-
eracy are being caught up in the ‘global search for human subjects’
(Petryna, 2009). In the ensuing debates, ERCs ﬁgure as both a key
mechanism in enabling trials as well as a site of potential activism
aimed at drawing attention to abuses and the broader issues of
inequality that often underpin these. ERC members frequently
indicated their awareness of vulnerable research subjects and their
duties and responsibilities in ensuring their protection:
.. the people who are in the ethics committee, they really see to it
that the patient’s rights are properly taken care of. because they
don’t know anything scientiﬁcally India, ERC member [003]
The problems identiﬁed, however, were not just downward
facing ones. ERC members in each country spoke of their re-
sponsibilities to feed issues and concerns up into legal and policy-
making machinery. Here, the concerns were much more about
‘national’ interest and how it might be sidelined, undermined or
over-ridden in the quest for viable experimental economies. One
informant spoke of ‘research coolies’, an emotive term intended to
invoke parallels with other arena in which domination and
exploitation of developing world populations is underway. This was
particularly so in India following a change of law in 2005 which
allowed easier access to pharmaceutical companies to local pop-
ulations (see Nundy and Gulhati, 2005). Similar, sentiments were
evident in Sri Lanka:
. the problem is we need to upgrade our societal knowledge levels,
preparedness must be upgraded, if that [successful engagement
with international clinical trials] is to actually work in that way,
otherwise it won’t, it will be a new kind of colonialism. That’s the
problem. Sri Lanka ERC member [074]
In response to these problems, members of ERCs spoke opti-
mistically of a progressively stronger, more conﬁdent and better
organised infrastructure out of which robust and consistent re-
sponses could be applied to international and locally sponsored
research proposals
.. we have a strong procedure right now. Earlier there was
hardly any procedures and now we have an application form,
even including a standard operating procedure is available for
the investigators to check..[].. one of the biggest advantages came
for the ethics review parties the ICMR guidelines which came in
2004, ‘05 which actually helped a lot to formulate how an ethics
committee should function in the country. India ERC member
[009]
. ethics committees have evolved. The type of questions that we
use to ask and the issues we used to raise 10 years ago are different
from what we raise now. And by and large the bar has risen. And
therefore even investigators have refused trials, I know. And in fact
many of them involve me in that pre-nup discussion. You know,
before they ﬁrm up with the company they will, they have ethical
issues they want to know from me also whether these are ethical
issues, whether these will cause problems. So they dowant to iron it
out. .[].. the investigator community needs to be convinced that
the ethics committee is a policeman, but a strict policeman, but not
somebody who is against us. But [someone] who wants to promote
good ethical research. And has ultimately got the patient’s good at
heart. India ERC member [002]Yet, despite these claims to progress, there was a sense in which
thework of committee members was a small response in the face of
a much bigger problem. Most of the ERC members interviewed
were voluntary. Their work involved long hours and exacting work
dealing with an unfeasible workload with the threat of possible
hostility from researchers in the background should they give
unfavourable decisions. Nonetheless, many of those interviewed
expressed strong commitment and dedication to their work.
Indeed, some spoke with enthusiasm bordering on evangelical zeal
about the importance of ethical review and the need to extend its
scope and improve its thoroughness.
However, the management of ethical review in practice was
likely to be rather more pragmatic and tactical. As a comment from
a member of an ethics committee in India makes clear, social and
humanitarian concerns are less in evidence as other priorities take
over
.. according to me if a person is recruited as a subject of research
and it is deemed by a component ethical review board and set of
researchers, that there is no ethical wrong or scientiﬁc wrong in
that person being recruited I don’t see why Indian subjects can’t be
recruited for clinical trials. So, yes, ok Indian patients are being
made guinea pigs for molecules. If it is being done in the right way I
don’t see anything wrong.[].. I suppose there are many agencies
which are conducting clinical trials which are not earlier into
ethical standards or scientiﬁc standards that is required. I don’t
know about that. But as far as we are concerned I don’t see any-
thing wrong. India ERC member [001]
In this rather straight up and down reading of ethical review, the
scope and function of ERCs is simple and clearly limited to the
research protocol and the assurances given therein. The attraction
of this approach, particularly among younger researchers, appeared
to be that it offers both procedural efﬁciency and authoritative
outcomes in circumstances where complexity and the sheer vol-
ume of work might otherwise overwhelm. In the midst of this
tension, our research identiﬁed a powerful and emerging align-
ment. Inmanaging the growing volume of protocols to review, ERCs
appeared to be cleaving to ICH-GCP as a route to procedural clarity.
At the same time, they also found themselves in competitionwith a
new breed of ‘independent’ and, indeed, internationally sponsored
ERCs.
These organisations were beginning to feature in the ethical
review landscape of India and to a lesser extent in Sri Lanka.
Constituted and practicing in conformity with ICH-GCP from their
inception, they offer a commercial route to ethical approval. Their
emergence causes concern to those who have laboured to develop
capacity and rigour in the work of institutional review bodies.
Concerns expressed were twofold. First, the guidelines followed
can be interpreted quite minimally and speciﬁcally and whilst
scientiﬁc rigour is likely to be guaranteed [because otherwise the
validity of the data would be compromised] issues of patient safety
are likely to be treated in a more procedural fashion.
Furthermore, a route to ethical approval which circumvents a
more politicised reading of ethics and what it means to protect a
‘subject’ is highly attractive to those wishing for a speedy review.
This tension is most evident in industry sponsored clinical trials
which are likely to be multi-centred. Here industry standards
enshrined in the ICH GCP create expectations of high levels of
conformity between trials. ERCs have less of a role to play in such
trials, primarily because the protocols are less negotiable but also
because large pharma companies, particularly foreign ones, have
both the resources and the experience to draft scientiﬁcally sound
and ethically plausible protocols. As one PI on a commercial trial in
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the Indian population. That’s all. Nothing more’ India Clinical Trial PI
[004]. In the drive towards procedural efﬁciency and auditable
outcomes, trialists, both commercial and non-commercial, end up
paying less attention to the wider socio-economic contexts in
which trials take place. Complex questions of just what is informed
consent and how to get it, and what the beneﬁts are for those who
participate in research are apt to be occluded in the face of pharma
induced proceduralism. This is not to say that these issues are ab-
sent from protocols but rather that, in the complex chains of re-
sponsibility and accountability that lie between a professionally
crafted and ethically approved application and its implementation
on the ground, there is much scope for the interests of trial par-
ticipants to become secondary to the conduct of the trial and the
data it sets out to generate. This problem is further compounded by
the fact that it is often junior staff with minimal training who are
responsible for the implementation of agreed protocols at the level
of day to day interaction with research participants.
The emergence of independent ethics committees within the
ERC landscape adds further momentum to this process, with con-
cerns being expressed about their independence (Karam and
Karandikar, 2012); also see (Emanuel et al., 2006). For many of
those interviewed, ethical review was not a legitimate area for
commercial activity because of the tension it creates between
robustness of review procedures on the one hand and the likeli-
hood of future use of particular ERCs by CROs and their sponsors on
the other:
.. If an independent ethics committee is very cautious, and they fear
that if they don’t approve, it [the trial] easily goes elsewhere and
they get the approval from there. Like EC shopping. There is nothing
to prevent that. India ERC member [002].
The minute they realize that there is something going wrong, when
we ask uncomfortable questions, they just go to some other com-
mittee India ERC member [001]
At the time of writing [Jan 2014] the Drug Controller General of
India has forbidden independent ethics committees from
approving clinical trial protocols following complaints about pro-
cedural irregularities.5 Further steps have been taken by the Su-
preme Court of India to establish more stringent monitoring of
trials including registration and accreditation of ERCs which will, in
future, also have increased responsibilities for monitoring and
reporting.6 Neither Sri Lanka nor Nepal has the kind of demand that
would currently make independent ethics committees viable.
Nonetheless, as we will see in the next section the issues of legit-
imacy and jurisdiction that their existence raises is much wider
than India alone.
6. ERCs and the question of legitimacy and authority
ERCs feature in a complex landscape of interests and concerns.
These are at once economic and humanitarian; legal and social;
national and international. Procedural legitimacy and authority is
drawn from their location within particular institutions. These
include Universities, Professional Associations, Hospitals and gov-
ernment departments and institutes with committees assembled
out of suitably representative experts. ERCs also derive their5 http://pharmabiz.com/ArticleDetails.aspx?aid¼76984&sid¼1 accessed 13th
August 2013.
6 Government set to tighten clinical trial norms. Times of India 3/01/2014. http://
articles.timesoﬁndia.indiatimes.com/2014-01-03/india/45834762_1_clinical-trials-
accreditation-council-ethics. accessed 10th Jan 2014.authority from a patchwork of guidelines and regulations that
emanate from different sources: government, industry, academia
and international NGOs. Reference to these sources enables ERCs to
gain credibility and acceptance among local and international re-
searchers. They provide members with an ethical charter of sorts
which validates and legitimates action.
We are SIDCER approved, and basically.[]., there is the FERCSL
national guidelines on writing your standard operating procedures
and doing the ethics review and we basically follow that to the
letter, so our SOPs is already readily available you can ﬁnd it or I
can give you a copy, everything is in writing and it’s very easy to
understand, it’s all tick boxes and check lists and we are very
transparent in the whole review, so really that’s what we follow
and at the moment we are reviewing our SOPs also, and probably
that’s of course just our procedures I think you may have to also
look at our criteria for review and see whether we can improve on
that. It is very standard everybody does the same thing within our
EC. Sri Lanka ERC member [071].
. we have developed our SOP’s based on ICMR, ICH and FERCAP
guidelines, so we follow those. And now because we have a SOP we
are stronger in saying certain things e India ERC member [156].
Unlike in Sri Lanka and Nepal, there is an expectation in India
that the responsibilities that ﬁgure in a research application will be
legally recognised and approved:
Interviewer: In India CRO PI, investigator and director all sign an
agreement relating to the collaboration?
Respondent: Yes. That is reviewed. But it comes to the ethics
committee; it also goes to our legal expert. You have a (hospital
ethics committee) legal expert. He also clariﬁes that, gets things
done the way the hospital is supposed to have it legally and it also
comes to the ethics committee to have a ﬁnal look at that. This goes
simultaneously; when they put in support for the scientiﬁc review
they will immediately send the CTA to the legal expert ofﬁce. India
ERC member [156].
Whilst these forms of regulatory triangulation increase conﬁ-
dence, they also raise concerns about over-excessive and disabling
regulation among researchers. ERCs asmechanisms that enable and
facilitate better research, give way to rather more antagonistic
readings of the role of ERCs among researchers with concerns
expressed that ERCs address problems that are not within their
sphere of responsibility:
I mean we are talking about ethics; we are talking about bad sci-
ence which is impeaching on ethics. They do ask, ‘who are you,
what is this? This is (name of the respondent)’s EC please, we
should try to avoid it’. So we have people like that. So it’s not that
simple. . whoever has to work as regulators are never popular
people, by deﬁnition. India ERC member [002]
However, in contexts where authority is weak and mistrust is
high, invoking rhetorics of legitimacy, such as audit, monitoring,
surveying and certiﬁcation by higher authorities, is one of the few
strategies available to persuade outsiders of the committee’s au-
thority to make legitimate pronouncements on the ethics of
research. Such credentials are essential when it comes to an ERCs
ability to act as what Stark has referred to as a ’declarative body’,
that is, one capable of making judgements and evaluations but,
most critically, decisions which will be accepted as emerging from a
democratic process (Stark, 2012, pp. 4e5).
B. Simpson et al. / Social Science & Medicine 131 (2015) 247e254252The power of ERCs is, therefore, largely negotiated rather than
absolute, based on guidelines rather than laws and persuasion rather
than instruction.Whilst great strides have beenmade in channelling
more research through ERCs and cultivating the conﬁdence of re-
searchers, there remain anxieties about the limits of their power and
a sense that all their good work might be undone once the project
passes beyond the ERC and into its implementation phase. For
example, in Nepal and Sri Lanka, once a project is approved it is very
much amatter of trust and investigators’willingness to self-reporton
how the trial is implemented. For one of our informants, this issue
was further linked with lack of capacity within the committee:
. there’s no training, we don’t have people who have trained in it
[ethical review], it needs training, monitoring, for the moment we
have done the consent monitoring and then we have depended on
adverse events from the investigators, ..[]. We do not have the
stafﬁng or the training. Sri Lanka ERC member [076]
For this ERC member, establishing a functioning ERC, simply
served to highlight the partiality of the process; there was an
awareness that many further steps would need to be taken to
ensure that monitoring was both comprehensive and rigorous. The
committee simply made apparent the magnitude of the problem of
policing projects once approved.
Problems of ERC scope, however, are not just about jurisdiction.
Other concerns arise for ERC members when they consider the
limits of their roles and responsibilities towards subjects who they
will never know. The moral complexity of the issues that they are
expected to deal with are substantial. As one of our Indian in-
formants candidly put it:
.. I ﬁnd it very difﬁcult to put myself in the feet of the completely
uneducated women fromUttar Pradesh. I ﬁnd it impossible to do so.
Which means to know how she would think and how she would
react to a situation is impossible forme?Whichmeans thenwe need
them [ERC members] to discuss this, to come up with a guidance
document. Like I told you, to talk to this cancer survivor, completely
different thought process came in tomymind, that you have to think
of it from too many different sources. India ERC member [002].
What this quotation points to, is a profoundly humanistic
conception of the role of ERCs but one that is often lost to procedure
and pragmatism. The starting point for any application is a research
protocol. The style of the protocol is invariably technical and con-
structed in such a way that researchers and ‘subjects’ are described
impersonally and with maximum detachment e socially and
culturally these documents are ﬂat, and intentionally so. It is the
skill of the person drafting the research protocol, and particularly in
pharmaceutically sponsored multi-centred trials, to produce such
documents. However, through ethical review, there is some pre-
sumption that the social imagination of the reviewers will be
brought into play. It is, in theory at least, the task of the ethics
committee to animate the protocol, that is, to try to imagine the
people who are likely to end up in the trial and the worlds inwhich
they live. Arguably, this is why social scientists and lay people are
brought on to ERCs and why there is currently a great deal of in-
terest in community advisory boards as ways of amplifying the
voice of those who end up in trials (Weijer and Emmanuel, 2000).
The purpose of such a mechanism is precisely to help stimulate acts
of imagination and empathy capable of invoking the people and
relationships with which the protocol will ultimately engage.
. you can’t deﬁne risk only as physical risk. People just forget
social risks, economic risks and psychological risks. India ERC
member [002].However, putting oneself in another’s shoes in the context of a
busy ERC is both challenging, time consuming and deemed by some
to be wholly misplaced. Consequently, there is a danger that the
human subject that features at the heart of an ERC’s deliberations
will not be any actual person in a real place and time but the trans-
cultural, trans-historical, universal subject which features in all
protocols. At this juncture, ICH-GCP offers an attractive route to
consistency in the conduct of clinical trials and particularly its focus
on the informed consent transaction as the primary index of ethical
conduct. However, the economic and cultural questions that exer-
cise some ERC members are apt to be obscured or overlooked.
In India in particular, limitations in terms of resources, training
and the absence of clearly deﬁned statutory duties render the limits
of ERC responsibilities fuzzy at the margins. Indeed, the scale and
complexity of activity means that the possibilities for breaches of
regulation are rife. A current concern of a number of informants
was the potential for moving activity to the edges of regulatory
reach whether this be in terms of the regions in which trials are
conducted or the committees through which trials are put. As a
result there have been calls for ERCs to have ‘teeth’ and a clearer
articulation with law and state regulation. Proposals to amend the
Drugs and Cosmetics Act [1940], as mentioned above, have speci-
ﬁed that ethical approval for clinical trials can only be given by ERCs
that have been registered with the licensing authority. This devel-
opment further ties in the practice of clinical trials with the ICH-
GCP India Guidelines via the formal registration of ERCs. The
amendment also gives the Central Drugs Standard Control Orga-
nisation the power to inspect the documentation of an ERC at any
time.
7. Conclusion
We began our considerations of ERC members’ views with a
question: if ethics committees are the solution what is the prob-
lem? In reﬂecting on the impacts of industry sanctioned models
and strategies for ethical review in the developing world it would
seem that there are a range of problems, some of which extend the
business of human subject protection beyond the immediate
engagement between a trial participant and a treatment being
tested in an RCT. In this article we have provided insights from
those who are, in many respects, at the eye of the storm when it
comes to the governance of clinical trial activity. On the one hand,
ERC members articulate a need for contextualisation and local-
isation in the attempt to render trials ethical in developing world
settings (cf Emanuel et al., 2004; Lavery et al., 2007). Here, ERC
members we interviewed, allude to issues that confound their ef-
forts to protect subjects, such as poverty, literacy and structural
inequality. Achieving a satisfactory ethical review might, in other
words, inspire advocacy and social critique. On the other hand,
however, they face considerable pressure. Their workload is sub-
stantial, they are under-resourced and there is a strong push to
standardise and regularise the work of ethical review in ways that
remove the independence of reviewers to set the scope of their
concerns.
These tensions are not just national or indeed regional phe-
nomena but are fuelled by changes that are taking place in Europe
and US which are aimed at increasing research capacity and ve-
locity by means of an alignment between ethical review and in-
dustry standards and procedures. For example, at the time of
writing, the EU is proposing to replace the existing clinical trials
directive with a new regulation aimed at accelerating application
procedures and harmonising administrative requirements for
multi-centre trials across the European Union and in countries
participating in trials beyond the EU (Den Boer and Schipper, 2013).
In the US, Food and Drugs Administration (FDA) proposed that the
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(ICH-GCP) be designated as the new regulatory standard which in
effect sidelined the Declaration of Helsinki for trials carried out
outside the US (Goodyear et al., 2009). Both of these developments
have signiﬁcant implications for the role that ethical review might
play in attempts to safeguard trial participants from harm and
exploitation. Given that ethics committees may not be able to
provide the kinds of protection that vulnerable people need we
ought to ask a further question: if ethic committees are the prob-
lem, what is the solution?
That ethics committee are currently a problem in the countries
considered might be inferred from the ways in which clinical trials
activity has generated debate, stimulated activism and stirred those
responsible for the governance of research to put forward improved
regulatory responses. For example, since our data was collected,
responses to public concerns over clinical trial regulation in India
have resulted in a wide range of new regulations coming from the
Supreme Court, the Ofﬁce of Drugs Controller General of India and a
series of expert panels. Registration of ethics committees, audio-
video recoding of the informed consent procedures and clearer
rules regarding compensation for deaths and injuries that occur
during clinical trials are all now mandatory.7 In Sri Lanka, the
drafting of a new Clinical Trials Act has provoked controversy as it is
believed by some to lower the regulatory threshold therebymaking
it easier to conduct clinical trials (Siribaddana and Bandara, 2013).
In Nepal, whilst debates about commercial trials have only just
begun, there is much interest in regulating research activities and
promoting ethical standards in the conduct of both clinical and
public health research. Signiﬁcantly, in each of these places, ERCs
are identiﬁed as the problem but they are also identiﬁed as the
solution when it comes to better research governance.
Yet, when it comes to what constitutes effective and legitimate
ethical review, the language of ICH-GCP is a strong card to play. One
of the reasons for this is the ease with which techniques of veriﬁ-
cation such as monitoring, audit, record keeping, documenting and
other evidence making procedures familiar to scientists, can be
imported into the practice of ethical review. However, the failure of
ethical review to protect human subjects beyond the informed
consent transaction does not result in a change of method but
typically better monitored replications of the same process (cf
McGoey, 2010). One consequence of this move in the US has been a
tendency to replicate the evidential turn in science through an
evidence-based ethics in that it would similarly, ’.. emphasize the
importance of data in informing decision and decision-making
about the ethical issues inherent in clinical medicine and
research’ (Sugarman, 2004, p. 495). The tendency to instrumen-
talise ethics in this way was evident in the accounts of a number of
researchers interviewed. Rather than seeing the directives of an
ERC as the beginning of an ongoing awareness of the wide-ranging
vulnerability of their subjects, many researchers spoke of ethics as a
kind of object; something obtained from, or ‘given’ by, the ERC
which then enabled them to continue with a clear conscience.Acknowledgements
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